Fabrice Barlesi, MD, PhD, on Resectable NSCLC: IPH5201 Plus Durvalumab and Platinum-Based Chemotherapy

April 21, 2026 By The ASCO Post Staff

Fabrice Barlesi, MD, PhD, of Gustave Roussy, discusses interim results from the phase II MATISSE trial, which looked at dual CD39 and PD-L1 inhibition in patients with resectable non–small cell lung cancer (NSCLC). The study investigated the combination of IPH5201, an investigational anti-CD39 monoclonal antibody, and the immune checkpoint inhibitor durvalumab plus platinum-based chemotherapy (Abstract CT231). 

Related Content